CION Ameerpet
Lynch syndrome is the hereditary cancer syndrome people have usually not heard of. It raises ovarian cancer risk — but bowel and womb cancer risk are considerably higher, and that is where the management effort goes.
Almost everyone has heard of BRCA. Very few people have heard of Lynch syndrome, despite it being a common hereditary cancer predisposition — and that gap in recognition is itself the main problem, because a great many carriers are never identified.
The mechanism involves a different repair system from BRCA. The mismatch repair genes — MLH1, MSH2, MSH6 and PMS2, along with EPCAM which switches MSH2 off — proofread newly copied DNA and correct the small errors that occur during cell division. When that proofreading fails, errors accumulate quickly, particularly in tissues where cells divide rapidly.
That explains the pattern of cancers. The bowel lining and the womb lining both renew constantly, which is why colorectal and endometrial cancer risk are by far the highest in Lynch syndrome. Ovarian cancer risk is genuinely raised too, but it sits behind those two — and any sensible management plan reflects that ordering rather than treating all three equally.
Mismatch repair genes correct copying errors in new DNA. When they fail, errors pile up in rapidly dividing tissue.
Both linings renew constantly, so they accumulate errors fastest. Ovarian risk is real but secondary.
Far less known than BRCA, which is the main reason carriers go unidentified for generations.
For Lynch syndrome, colonoscopic surveillance does something no ovarian screening can: it is genuinely preventive rather than merely detective. Colonoscopy finds precancerous polyps and removes them in the same procedure, so the cancer never forms — and regular colonoscopy in Lynch carriers substantially reduces both colorectal cancer incidence and mortality. This is the sharpest possible contrast with ovarian cancer, where no surveillance has been shown to reduce deaths. It is also why, for a Lynch carrier, the bowel surveillance schedule is the single most important thing to get right. Source: NCCN Genetic/Familial High-Risk Assessment: Colorectal guidelines.
Risk varies considerably by which gene is involved — more so than in BRCA — which is why identifying the specific gene matters for planning.
| Cancer | General population | Lynch syndrome (approximate range) |
|---|---|---|
| Colorectal | Roughly 4-5% | Substantially raised; highest with MLH1 and MSH2 |
| Endometrial (womb) | Roughly 3% | Substantially raised; highest with MSH6 alongside MLH1 and MSH2 |
| Ovarian | Roughly 1-2% | Moderately raised; higher with MSH2 than with PMS2 |
| Stomach, small bowel, urinary tract | Low | Modestly raised, varying by gene |
| PMS2 carriers overall | — | Lowest risks of the Lynch genes; surveillance is adjusted accordingly |
*Lifetime risk estimates vary widely between published studies and differ substantially by gene, so specific figures are best discussed with a genetics service using your own gene and family history. This table gives the ordering, which is the part that shapes management.
The plan is broader than for BRCA because more organs are involved — and the ovarian part is usually the smaller half of the gynaecological conversation.
Regular colonoscopy, typically every one to two years and starting considerably earlier than population screening, is the single most effective intervention in Lynch syndrome. It is preventive rather than merely detective: precancerous polyps are found and removed during the same procedure, so the cancer never develops.
The interval is shorter than for the general population because Lynch-associated polyps can progress to cancer faster. Keeping to the schedule matters more than almost anything else on this list, and it is worth establishing clearly who arranges each one. See colon cancer and rectal cancer.
Womb cancer risk in Lynch syndrome is substantially higher than ovarian cancer risk, and it is frequently the first Lynch-associated cancer a woman develops. Fortunately it usually announces itself early through abnormal or post-menopausal bleeding, which is why any such bleeding in a carrier warrants prompt assessment.
Awareness of that symptom is a genuinely effective strategy. Some carriers are also offered endometrial sampling or ultrasound surveillance, though the evidence for these is weaker than for colonoscopy. See bleeding after menopause and endometrial cancer.
For Lynch carriers, risk-reducing surgery generally means hysterectomy with bilateral salpingo-oophorectomy together — removing the womb as well as the ovaries and tubes. This differs from BRCA, where the uterus is usually retained, and it reflects the fact that endometrial risk is the larger of the two.
Timing is individualised and typically discussed after childbearing is complete, often around 40 to 45 depending on the gene and family history. It brings surgical menopause forward, so hormone replacement should be planned in advance. See risk-reducing surgery.
There is reasonable evidence that regular aspirin reduces colorectal cancer risk in Lynch syndrome, and it is commonly discussed with carriers. Dose and duration are matters for individual medical advice, since aspirin carries its own risks including bleeding, and it should not be started without discussing it with your doctor.
General measures apply too — not smoking, maintaining a healthy weight, and managing the metabolic factors that independently raise endometrial cancer risk. These are worth attention rather than dismissal, particularly the weight-related endometrial risk.
Ovarian cancers arising in Lynch syndrome tend to behave somewhat differently from sporadic ovarian cancer. They occur at a younger average age, are more often non-serous subtypes such as endometrioid and clear cell, and are more frequently diagnosed at an earlier stage.
This is a meaningfully better position than the typical late-stage high-grade serous presentation, though it does not remove the need for the risk to be managed. It also means that a young woman with an endometrioid or clear-cell ovarian cancer should have Lynch syndrome considered, even without a striking family history.
Many people with Lynch syndrome are identified not through family history but through their own tumour. Bowel and endometrial cancers are now routinely tested for mismatch repair deficiency using immunohistochemistry or microsatellite instability testing, and an abnormal result prompts referral for germline genetic testing.
This route catches families with no obvious pattern — small families, families where relatives died young of other causes, or where the history simply was not asked about. If you or a relative has had bowel or womb cancer, it is reasonable to ask whether that tumour was tested.
Any one of these is a reasonable reason to seek genetic counselling. You do not need the whole set.
A close relative diagnosed young is one of the strongest single signals, and it is often the first clue in a family.
Endometrial cancer is frequently the first Lynch-associated cancer in a woman, and it is easily overlooked as a signal.
In the same person, or across relatives on the same side of the family. This combination is the classic Lynch signature.
Bowel, womb, ovary, stomach, small bowel and urinary tract cancers clustering on one side of a family.
Someone who has had two Lynch-associated cancers, or bowel cancer twice, warrants a genetics discussion.
Mismatch repair deficiency or microsatellite instability reported on a bowel or womb tumour prompts germline testing.
Lynch syndrome passes through fathers as readily as mothers. A quiet maternal side proves nothing, and small families can hide the pattern entirely.
It removes precancerous polyps before they become cancer. For Lynch syndrome, that makes surveillance genuinely preventive rather than merely detective.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling and panel testing covering the Lynch genes are delivered in-house at CION.
The commonest way Lynch syndrome is missed is that nobody asks the right question. A woman being assessed for ovarian cancer risk is asked about breast and ovarian cancer in the family; her father's bowel cancer at 47 never comes up, because it did not seem relevant to a gynaecological consultation.
Your first consultation at CION is free and runs to about 45 minutes, and genetic counselling and multi-gene panel testing covering the Lynch genes are delivered in-house. The family history taken here covers bowel, womb, ovarian, stomach and urinary tract cancers on both sides — because that is what the pattern actually looks like, and asking narrowly is how it gets missed.
We will also be clear about where the effort should go. For a Lynch carrier, keeping to the colonoscopy schedule matters more than anything on our ovarian pages, because it genuinely prevents cancer rather than merely finding it. Where cancer does develop, CION delivers medical oncology in-house across 35+ centres; gynaecological and bowel surgery is coordinated with specialist partner centres and may be billed there.
Multi-gene panel testing covering MLH1, MSH2, MSH6, PMS2 and EPCAM alongside the BRCA genes.
Bowel, womb, ovary, stomach and urinary tract, on both sides. Asking narrowly is how Lynch gets missed.
For a Lynch carrier the bowel surveillance schedule matters more than anything on our ovarian pages. We say so.
Risk-reducing hysterectomy with salpingo-oophorectomy is performed at specialist partner centres and may be billed there.
Both are hereditary cancer syndromes affecting ovarian risk, and they are managed quite differently.
| BRCA1 / BRCA2 | Lynch syndrome | |
|---|---|---|
| Genes involved | BRCA1, BRCA2 | MLH1, MSH2, MSH6, PMS2, EPCAM |
| Repair mechanism affected | Homologous recombination (double-strand breaks) | Mismatch repair (copying errors) |
| Main cancers | Breast and ovary | Bowel and womb, then ovary |
| Ovarian risk | High, especially BRCA1 | Moderately raised |
| Does surveillance work? | Yes for breast; no for ovary | Yes for bowel — colonoscopy is preventive |
| Risk-reducing surgery | Salpingo-oophorectomy; uterus usually kept | Hysterectomy with salpingo-oophorectomy together |
| Typical ovarian subtype | High-grade serous | More often endometrioid or clear cell, younger, earlier stage |
*Both are inherited in an autosomal dominant pattern, so each child of a carrier has a fifty per cent chance of inheriting the variant, and both pass through fathers as readily as mothers.
It is an inherited cancer predisposition caused by a pathogenic variant in one of the DNA mismatch repair genes — MLH1, MSH2, MSH6 or PMS2 — or in EPCAM, which switches MSH2 off. These genes proofread newly copied DNA and correct small errors that occur during cell division. When that proofreading fails, errors accumulate quickly, particularly in tissues where cells divide rapidly. That is why colorectal and endometrial cancer risks are highest, with ovarian cancer risk moderately raised alongside smaller increases in stomach, small bowel and urinary tract cancer risk.
Moderately — the risk is clearly higher than the general population's roughly one to two per cent lifetime risk, but considerably lower than the bowel and endometrial cancer risks that dominate Lynch syndrome, and lower than BRCA1-related ovarian risk. It also varies substantially by which gene is involved, with MSH2 carrying higher ovarian risk than PMS2. Because published estimates vary widely between studies, specific figures are best discussed with a genetics service using your particular gene and family history rather than taken from a general table.
They affect different repair systems and produce different cancer patterns. BRCA1 and BRCA2 work in homologous recombination, repairing double-strand DNA breaks, and mainly raise breast and ovarian cancer risk. The Lynch genes work in mismatch repair, correcting copying errors, and mainly raise bowel and womb cancer risk with ovarian risk secondary. Management differs accordingly: colonoscopy is the cornerstone for Lynch and is genuinely preventive, and risk-reducing surgery for Lynch usually includes hysterectomy alongside removal of the ovaries and tubes, whereas for BRCA the uterus is normally retained.
Regular colonoscopy is the cornerstone, typically every one to two years and starting considerably earlier than population screening. Unlike ovarian screening, it genuinely prevents cancer, because precancerous polyps are found and removed in the same procedure. For gynaecological risk, awareness of abnormal or post-menopausal bleeding is the most effective measure, since endometrial cancer usually announces itself early that way; some carriers are also offered endometrial sampling or ultrasound, though the evidence is weaker. Aspirin is commonly discussed for bowel risk reduction and should be started only on individual medical advice.
It is generally discussed, though the timing and the decision are individual. For Lynch carriers, risk-reducing surgery usually means hysterectomy together with removal of both ovaries and tubes, because endometrial risk is the larger of the two gynaecological risks — this differs from BRCA, where the uterus is normally kept. It is typically considered after childbearing is complete, often around 40 to 45 depending on the gene and family history. It brings surgical menopause forward, so hormone replacement should be planned before surgery rather than raised afterwards.
It can, and this is exactly the connection that most often goes unnoticed. A family history of bowel cancer, particularly under 50, is one of the strongest signals of Lynch syndrome — and Lynch syndrome raises ovarian cancer risk alongside its much higher bowel and womb cancer risk. Because a gynaecological consultation typically asks only about breast and ovarian cancer in the family, a father's or grandfather's bowel cancer frequently never comes up. If bowel or womb cancer runs in your family, mention it explicitly, on either side.
Yes — genetic counselling and multi-gene panel testing covering MLH1, MSH2, MSH6, PMS2 and EPCAM alongside the BRCA genes are delivered in-house at CION. The first consultation is free and runs to about 45 minutes, and the family history taken here covers bowel, womb, ovarian, stomach and urinary tract cancers on both sides, since asking narrowly is how Lynch syndrome is most often missed. Medical oncology is delivered in-house across more than 35 centres; gynaecological and bowel surgery is coordinated with specialist partner centres and may be billed there.